Are people with HIV and HCV co-infection who are cured of hepatitis C with DAAs at increased risk for liver cancer?

People with HIV and hepatitis C virus (HCV) co-infection who are successfully treated for hepatitis C using interferon-free direct-acting antiviral (DAA) therapy do not appear to have an increased likelihood of developing hepatocellular carcinoma (HCC), according to a study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2017) this month in Seattle. More HCC cases are being diagnosed among people with co-infection cured of h

HCV Screening Shouldn’t Just Focus on At-Risk Populations

At the Conference on Retroviruses and Opportunistic Infections (CROI 2017) in Seattle, Washington, researchers from MedStar Health Research Institute in Maryland presented new data on hepatitis C virus (HCV)-positive non-baby boomers. It’s widely acknowledged that those individuals belonging to the baby boomer age group (those born between 1946 and 1964) are at higher risk of acquiring HCV infection. According to the Centers for Disease Control and Preven

Wide Use of New HCV Drugs Prevents New Cases — ‘Treatment as prevention’ possible

SEATTLE -- Unrestricted use of new direct-acting agents against hepatitis C (HCV) can markedly reduce the rate of new infections, a researcher said here. That's based on analysis of what happened in the Netherlands among gay men with both HIV and HCV when unlimited access to the new, highly effective agents was rolled out in 2015, according to Bart Rijnders, MD, PhD, of Erasmus University Medical Center in Rotterdam, the Netherlands. Uptake of the drug